OX2R Inhibitors
3 drugsAbout OX2R
Orexin receptor 2 (OX2R) is a G protein-coupled receptor that regulates wakefulness and sleep. Targeting OX2R modulates neuronal signaling to address sleep disorders.
OX2R is a therapeutic target for sleep disorders, but currently, there is no genetic evidence directly linking OX2R to specific diseases.
Three FDA-approved drugs, DAYVIGO, QUVIVIQ, and BELSOMRA, target OX2R, all of which are small molecules. These drugs are marketed by EISAI INC, IDORSIA, and Merck, respectively, for sleep-related conditions.
Top OX2R Drugs
The OX2R drug market is dominated by three companies: EISAI INC, IDORSIA, and Merck.
High market concentration suggests significant barriers to entry for new competitors.
OX2R Drug Modality Landscape
Modalities
Routes of Administration
OX2R is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
OX2R Clinical Trials 134 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on OX2R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 32 | 29 | 0 | 3 | 100% |
| Phase 2 | 42 | 16 | 6 | 18 | 73% |
| Phase 3 | 18 | 14 | 0 | 4 | 100% |
| Phase 4 | 42 | 21 | 5 | 16 | 81% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved OX2R drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting OX2R. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
OX2R Drug Approval Timeline (2014 - 2022)
The first OX2R-targeting drug was approved in 2014, with the most recent approval in 2022.
Relatively recent approvals suggest continued interest in OX2R as a therapeutic target, but the market may be approaching saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 67 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on OX2R. A trial counts if an approved drug acting on OX2R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.